ABSTRACT
Since its ™rst clinical trial in 1990 (Anderson 1992), the ™eld of gene therapy has grown exponentially and drawn more and more attention from the ™elds of biotechnology, pharmaceutical research, and medicine (Park et al. 2006; Ragusa et al. 2007). Despite the added attention, only a minor percentage of clinical trials utilizing gene delivery have reached phase III, which indicates the level of di±culty associated with the methods and the strict restrictions to such promising and at the same time risky treatments (Ragusa et al. 2007).
